In humans, acting as an antagonist of the farnesoid X receptor, which was once believed to result in decreased cholesterol synthesis in the liver.
Kubantu, kuba ngumphikisi we-farnesoid X receptor, eyake yakholelwa ukuthi ibangele ukwehla kwe-cholesterol synthesis esibindi.